ImmunoMind
Berkeley
About ImmunoMind
ImmunoMind improves the design of T-cell therapies by precisely identifying T-cell subpopulations and their immune profile. ImmunoMind’s Augmented Intelligence platform guides translational and clinical research to improve the product’s quality, safety and efficacy with single-cell precision. The platform is based on proprietary single-cell multi-omics technologies to automatically evaluate cell differentiation, estimate exhaustion rate of subpopulations and identify off-tumor targets. UC Berkeley SkyDeck’20 Alumnus.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $755.0K
- Funding stage: Seed
- Last round: Pre-Seed (Jan 2022)
- Website: immunomind.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Bioinformatics, Biotechnology, Genetics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immunomind-136793 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.